Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy
A phase 1/2 trial of Mavrostobart, Tislelizumab, Gemcitabine in non-small-cell lung cancer and small-cell lung cancer, run by Phanes Therapeutics, now recruiting.
Overview
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) is a phase 1/2 interventional study registered as NCT05431270 by Phanes Therapeutics, with 40 participants planned, started 2022-08-11 and due to reach its primary completion in 2027-12. Interventions recorded: Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed. Conditions listed: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialComparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Shares Tislelizumab, Pemetrexed, Paclitaxel / nab-paclitaxel, Small-cell lung cancer.
- TrialA Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Shares Tislelizumab, Pemetrexed, Paclitaxel / nab-paclitaxel, Small-cell lung cancer.
- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Pemetrexed, Gemcitabine, Paclitaxel / nab-paclitaxel, Small-cell lung cancer.
- TrialStudy of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Shares Pemetrexed, Gemcitabine, Paclitaxel / nab-paclitaxel, Small-cell lung cancer.
- TrialStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [
Shares Docetaxel, Pemetrexed, Gemcitabine, Small-cell lung cancer.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Gemcitabine, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Pancreatic ductal adenocarcinoma.
- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Docetaxel, Pemetrexed, Paclitaxel / nab-paclitaxel, Small-cell lung cancer.
- TrialSacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With
Shares Docetaxel, Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.